TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines.

Abstract:

:Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin induced DNA damage and apoptosis. TXNL1, a member of the thioredoxin family, negatively regulated the expression of XRCC1 via the ubiquitin-proteasome pathway. Here, we investigated the role of TXNL1 in the apoptosis induced by cisplatin. Our data showed that the expression of TXNL1 in the cisplatin resistant gastric cancer cell lines BGC823/DDP and SGC7901/DDP cells was significantly lower compared with the cisplatin sensitive cell lines BGC823 and SGC7901. Inhibition of the expression of TXNL1 in BGC823 and SGC7901 cells led to increased resistance to cisplatin induced apoptosis and cell death detected by Tunel and clonogenic assay, respectively. In contrast, over expression of TXNL1 in BGC823/DDP and SGC7901/DDP cells lead to higher cisplatin induced apoptosis and cell death. Moreover, our results demonstrated that the mechanism of TXNL1 regulating cisplatin-induced apoptosis was closely associated with Bcl-2 mediated mitochondria apoptosis pathway. In conclusion, these findings suggest that TXNL1 was a feasible modulator and potential chemotherapeutic target for the cisplatin resistant phenotype of human gastric cancer cells.

authors

Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

doi

10.2174/1568009614666141028094612

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

850-9

issue

9

eissn

1568-0096

issn

1873-5576

pii

CCDT-EPUB-63079

journal_volume

14

pub_type

杂志文章
  • Integrins in cancer treatment.

    abstract::Anchorage-independent growth, anoikis resistance, and most steps of metastasis formation are integrin-mediated or -dependent processes, which are characteristics of malignant tumor cells. Acting as oncogenes or tumor suppressor genes, integrins may be involved in the oncogenic transformation of normal cells and their ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800906776056518

    authors: Eble JA,Haier J

    更新日期:2006-03-01 00:00:00

  • Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?

    abstract::Cancer is a disease in which cellular growth regulatory networks are disrupted. Lesions in well-characterized oncogenes and tumor suppressors often contribute to the dysregulation, but recent work has also uncovered the fundamental importance of enzymes that modulate the acetylation status of chromatin to the initiati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009033481994

    authors: Chen JS,Faller DV,Spanjaard RA

    更新日期:2003-06-01 00:00:00

  • Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.

    abstract::Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907781662284

    authors: Warlick ED,Smith BD

    更新日期:2007-09-01 00:00:00

  • Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment.

    abstract::One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009617666171114143330

    authors: Lisiak N,Toton E,Rybczynska M

    更新日期:2018-01-01 00:00:00

  • Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

    abstract::Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800906777441780

    authors: Auberger J,Loeffler-Ragg J,Wurzer W,Hilbe W

    更新日期:2006-06-01 00:00:00

  • Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy.

    abstract::Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009617666170330124819

    authors: Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

    更新日期:2018-01-01 00:00:00

  • Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

    abstract::The treatment of advanced non � small cell lung cancer (NSCLC) increasingly involves the use of molecularly targeted therapy with activity against either the tumor directly, or indirectly, through activity against host-derived mechanisms of tumor support such as angiogenesis. The most well studied signaling pathway as...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912799095144

    authors: Kono SA,Heasley LE,Doebele RC,Camidge DR

    更新日期:2012-02-01 00:00:00

  • Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies.

    abstract::The evolution of genomic research enabled the genetic and molecular profiling of breast cancer and revealed the profound complexity and heterogeneity of this disease. Subtypes of breast cancer characterized by mutations and/or amplifications of some proto-oncogenes are associated with an increased rate of recurrence a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160603123014

    authors: Guerram M,Hamdi AM,Zhang LY,Jiang Z

    更新日期:2017-01-01 00:00:00

  • Lipoamino acid prodrugs of paclitaxel: synthesis and cytotoxicity evaluation on human anaplastic thyroid carcinoma cells.

    abstract::Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800909787580944

    authors: Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

    更新日期:2009-03-01 00:00:00

  • The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

    abstract::The total expression profiles of two medulloblastoma cell lines resistant to the preactivated form of cyclophosphamide (4-hydroperoxycyclophosphamide, 4-HC) were examined using the Affymetrix GeneChip U133A array. Our primary objective was to look for possible genes, other than the well-studied aldehyde dehydrogenases...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800908784293631

    authors: Bacolod MD,Lin SM,Johnson SP,Bullock NS,Colvin M,Bigner DD,Friedman HS

    更新日期:2008-05-01 00:00:00

  • Control of copper status for cancer therapy.

    abstract::Copper is a trace element which is tightly regulated in mammals and lower animals. Disruptions of copper homeostasis in humans are rare and they cause serious disorders such as Wilson's disease and Menke's disease. Copper plays an important role in promoting physiological and malignant angiogenesis. Formation of new b...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800905774574066

    authors: Goodman VL,Brewer GJ,Merajver SD

    更新日期:2005-11-01 00:00:00

  • The anti-tumor effect and mechanisms of action of penta-acetyl geniposide.

    abstract::Gardenia, the fruit of Gardenia jasminoides Ellis, has been widely used to treat liver and gall bladder disorders in Chinese medicine. It has been shown recently that geniposide, the main ingredient of Gardenia Fructus, exhibits the anti-tumor effect. In this review, we discuss the anti-tumor effect and possible mecha...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009054064633

    authors: Peng CH,Huang CN,Wang CJ

    更新日期:2005-06-01 00:00:00

  • The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.

    abstract:BACKGROUND:The solute carrier family 7 (SLC7) can be categorically divided into two subfamilies, the L-type amino acid transporters (LATs) including SLC7A5-13, and SLC7A15, and the cationic amino acid transporters (CATs) including SLC7A1-4 and SLC7A14. Members of the CAT family transport predominantly cationic amino ac...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009619666190802135714

    authors: Lu X

    更新日期:2019-01-01 00:00:00

  • Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.

    abstract::Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009618666181010091246

    authors: Liang Z,Lu Z,Zhang Y,Shang D,Li R,Liu L,Zhao Z,Zhang P,Lin Q,Feng C,Zhang Y,Liu P,Tu Z,Liu H

    更新日期:2019-01-01 00:00:00

  • Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.

    abstract::Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/15680096113139990038

    authors: Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

    更新日期:2013-07-01 00:00:00

  • The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration.

    abstract::Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increa...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009617666170208162058

    authors: Berretta M,Romano C,Di Francia R,De Diviitis C,Canzonieri V,Caraglia M,Facchini G,Nasti G

    更新日期:2018-01-01 00:00:00

  • Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.

    abstract::Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of our systemic analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to i...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009614666140821122718

    authors: Mielecki M,Milner-Krawczyk M,Grzelak K,Mielecki D,Krzysko KA,Lesyng B,Priebe W

    更新日期:2014-01-01 00:00:00

  • Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance.

    abstract::Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the uni...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009618666180628102247

    authors: Tandon I,Sharma NK

    更新日期:2019-01-01 00:00:00

  • Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

    abstract::Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800908786733450

    authors: Heng DY,Bukowski RM

    更新日期:2008-12-01 00:00:00

  • New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-positive chromosome deriving from a translocation between chromosomes 22 and 9. The oncogenic product of this aberrant chromosome is the constitutively active tyrosine kinase BCR-ABL that is responsible for leukemic cell growth,...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912800673239

    authors: Stefanachi A,Leonetti F,Nicolotti O,Catto M,Pisani L,Cellamare S,Altomare C,Carotti A

    更新日期:2012-06-01 00:00:00

  • Transcription factors: molecular targets for prostate cancer intervention by phytochemicals.

    abstract::With increasing incidence of cancer at most of the sites, and growing economic burden and associated psychological and emotional trauma, it is becoming clearer that more efforts are needed for cancer cure. Since most of the chemotherapeutic drugs are non-selective because they are also toxic to the normal cells, new a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907780809732

    authors: Kaur M,Agarwal R

    更新日期:2007-06-01 00:00:00

  • Cetuximab: from bench to bedside.

    abstract::Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910790980241

    authors: Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

    更新日期:2010-02-01 00:00:00

  • Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer.

    abstract::Membrane ion channels participate in cancerous processes such as proliferation, migration and invasion, which contribute to metastasis. Increasing evidence indicates that voltage-dependent K(+) (Kv) channels are involved in the proliferation of many types of cells, including tumor cells. Kv channels have generated imm...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800909790192400

    authors: Bielanska J,Hernández-Losa J,Pérez-Verdaguer M,Moline T,Somoza R,Ramón Y Cajal S,Condom E,Ferreres JC,Felipe A

    更新日期:2009-12-01 00:00:00

  • Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.

    abstract::The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009620666200424145622

    authors: Becker JS,Fathi AT

    更新日期:2020-01-01 00:00:00

  • nMET, A New Target in Recurrent Cancer.

    abstract::Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-d...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160105105250

    authors: Xie Y,Istayeva S,Chen Z,Tokay T,Zhumadilov Z,Wu D,Hortelano G,Zhang J

    更新日期:2016-01-01 00:00:00

  • Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

    abstract::Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/15680096113139990083

    authors: Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

    更新日期:2013-09-01 00:00:00

  • Regulation of mesenchymal phenotype by MicroRNAs in cancer.

    abstract::Epithelial-mesenchymal transition (EMT) is a developmental process that converts epithelial cells into migratory and invasive cells. This process also plays an important role in cancer progression and metastasis by enabling tumor cells to leave primary sites. EMT is regulated by complex transcription networks and post...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/15680096113136660098

    authors: Yan J,Gumireddy K,Li A,Huang Q

    更新日期:2013-11-01 00:00:00

  • Black currant anthocyanins abrogate oxidative stress through Nrf2- mediated antioxidant mechanisms in a rat model of hepatocellular carcinoma.

    abstract::Hepatocellular carcinoma (HCC), considered to be one of the most lethal cancers with almost > 1 million deaths reported annually worldwide, remains a devastating disease with no known effective cure. Hence, chemopreventive strategies come into play, offering an effective and safe mode of treatment, ideal to ward off p...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800912803987968

    authors: Thoppil RJ,Bhatia D,Barnes KF,Haznagy-Radnai E,Hohmann J,Darvesh AS,Bishayee A

    更新日期:2012-11-01 00:00:00

  • Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

    abstract::Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, en...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800912801784839

    authors: Matsuhashi A,Ohno T,Kimura M,Hara A,Saio M,Nagano A,Kawai G,Saitou M,Takigami I,Yamada K,Okano Y,Shimizu K

    更新日期:2012-07-01 00:00:00

  • Effects of Iron Chelation in Osteosarcoma.

    abstract:BACKGROUND:Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic properties in many tumors. Deferasirox is the most used iron chelator co...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009620666201230090531

    authors: Argenziano M,Di Paola A,Tortora C,Di Pinto D,Pota E,Di Martino M,Perrotta S,Rossi F,Punzo F

    更新日期:2020-12-29 00:00:00